Cutler Group’s Reata Pharmaceuticals, Inc. Class A Common Stock RETA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q3 | – | Sell |
-15,800
| Closed | -$287K | – | 4498 |
|
|
2023
Q2 | $287K | Sell |
15,800
-14,100
| -47% | -$1.33M | 0.04% | 494 |
|
|
2023
Q1 | $349K | Buy |
29,900
+28,900
| +2,890% | +$1.7M | 0.04% | 459 |
|
|
2022
Q4 | $3K | Sell |
1,000
-400
| -29% | -$13.8K | ﹤0.01% | 3591 |
|
|
2022
Q3 | $5K | Buy |
1,400
+600
| +75% | +$16.6K | ﹤0.01% | 3730 |
|
|
2022
Q2 | $3K | Sell |
800
-16,100
| -95% | -$480K | ﹤0.01% | 4169 |
|
|
2022
Q1 | $42K | Sell |
16,900
-3,500
| -17% | -$104K | ﹤0.01% | 2410 |
|
|
2021
Q4 | $10K | Buy |
+20,400
| New | +$1.58M | ﹤0.01% | 3742 |
|
|
2021
Q3 | – | Sell |
-100
| Closed | -$1K | – | 6591 |
|
|
2021
Q2 | $1K | Buy |
+100
| New | +$11.3K | ﹤0.01% | 5507 |
|
|
2021
Q1 | – | Sell |
-200
| Closed | -$6K | – | 6501 |
|
|
2020
Q4 | $6K | Buy |
+200
| New | +$26.3K | ﹤0.01% | 3581 |
|
|
2020
Q2 | – | Sell |
-11,000
| Closed | -$208K | – | 5055 |
|
|
2020
Q1 | $208K | Sell |
11,000
-2,000
| -15% | -$386K | 0.01% | 927 |
|
|
2019
Q4 | $771K | Buy |
13,000
+4,000
| +44% | +$730K | 0.05% | 323 |
|
|
2019
Q3 | $87K | Buy |
9,000
+8,300
| +1,186% | +$704K | 0.01% | 1161 |
|
|
2019
Q2 | $9K | Sell |
700
-2,300
| -77% | -$199K | ﹤0.01% | 2789 |
|
|
2019
Q1 | $4K | Buy |
+3,000
| New | +$249K | ﹤0.01% | 3106 |
|
|
2018
Q4 | – | Sell |
-8,800
| Closed | -$78K | – | 4782 |
|
|
2018
Q3 | $78K | Buy |
+8,800
| New | +$620K | 0.01% | 1344 |
|
Other funds holding RETA
Cutler Group's RETA Position: Q3 2023 in Review
Cutler Group sold out of Reata Pharmaceuticals, Inc. Class A Common Stock (RETA) in Q3 2023, closing a stake of 1,800 shares — an estimated $183K sold.
Cutler Group first reported a position in RETA in Q4 2017 and held it in 19 quarters. The position peaked at $360K in Q2 2019. 2 funds tracked by Wall St. Rank hold RETA as of Q3 2023.
- Cutler Group reported no remaining Reata Pharmaceuticals, Inc. Class A Common Stock position as of Q3 2023 after selling out during the quarter.
- Cutler Group sold 1,800 Reata Pharmaceuticals, Inc. Class A Common Stock shares in Q3 2023, an estimated $183K.
- Cutler Group first reported a position in Reata Pharmaceuticals, Inc. Class A Common Stock in Q4 2017 and held it in 19 quarters.
- Cutler Group's Reata Pharmaceuticals, Inc. Class A Common Stock position peaked at $360K in Q2 2019.
- 2 funds tracked by Wall St. Rank held Reata Pharmaceuticals, Inc. Class A Common Stock as of Q3 2023.
Based on Cutler Group's 13F filing for Q3 2023, filed 7 Nov 2023.